Utilization of MRD/ctDNA testing in bladder cancer and other GU malignancies

ctDNA is transforming MIBC care by enabling more precise detection of residual disease and recurrence risk, leading to more personalized treatment decisions.

ctDNA is emerging as a key tool alongside traditional biomarkers in MIBC by providing dynamic recurrence risk insights, though it is still in a transitional phase and not yet fully integrated into standardized treatment decisions.

Experts debate ctDNA/MRD testing cadence after cystectomy and EV‑pembro, highlighting risks, evidence gaps, and trials guiding therapy.

Clinicians increasingly use ctDNA testing earlier in bladder cancer care, with urologists ordering more and tumor-informed assays gaining traction and coverage.

ctDNA testing shifts to earlier ordering by urologists, speeding post-URBT decisions; clinicians favor tumor-informed assays like Signatera amid evolving coverage.

Urologists increasingly order ctDNA earlier, speeding bladder cancer decisions; experts discuss Signatera tumor-informed testing and evolving coverage.

Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.

Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.

ctDNA and KIM-1 reshape kidney cancer care, improving MRD detection, relapse risk stratification, and SBRT timing for therapy-free survival.

ctDNA and miRNA-371 liquid biopsies show promise for risk stratification in testicular cancer, guiding adjuvant and residual mass decisions.

Experts spotlight ctDNA gaps in upper-tract and bladder-sparing trials, plus microRNA advances, shaping MRD-guided cancer care.